Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.51 |
| ▸ | CLK2 | P49760 | 4/20 | 0.44 |
| ▸ | CLK1 | P49759 | 3/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1303593 | 0.89 | MAP3K5 (0.60) | MAP3K5CLK2CLK1PIK3CGPIK3CA | |
| SCHEMBL1303824 | 0.81 | RIPK1 (0.43) | MAP3K5CLK2CLK1PIK3CDPIK3CG | |
| SCHEMBL1302407 | 0.79 | MAP3K5 (0.44) | MAP3K5CLK2CLK1PIK3CDPIK3CG | |
| SCHEMBL1303492 | 0.78 | MAP3K5 (0.55) | MAP3K5CLK2CLK1PIK3CDPIK3CG | |
| SCHEMBL1303978 | 0.76 | MAP3K5 (0.58) | MAP3K5CLK2CLK1PIK3CGPIK3CA | |
| SCHEMBL12664788 | 0.73 | RIPK1 (0.46) | PIK3CDPIK3CGPIK3CBPIK3CAPI4KB | |
| SCHEMBL1303473 | 0.71 | MAP3K5 (0.48) | MAP3K5CLK2CLK1PIK3CDPIK3CG | |
| SCHEMBL1304315 | 0.71 | MAPK13 (0.39) | MAP3K5PIK3CDPIK3CGPIK3CBPIK3CA | |
| SCHEMBL12664731 | 0.71 | PIK3CA (0.53) | PIK3CDPIK3CGPIK3CA | |
| SCHEMBL3136768 | 0.70 | PIK3CA (0.63) | PIK3CDPIK3CGPIK3CBPIK3CAPI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2178868-A1 | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | claimed |
| WO-2009010530-A1 | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | claimed |
| US-8053574-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20100197682-A1 | Organic Compounds | NOVARTIS AG | 2010-08-05 | — | — | US | disclosed |
| EP-2178868-A1 | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009010530-A1 | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197682-A1 | Organic Compounds | PIK3CA, PI4KA, PI4KB | MAP3K5 160/4885CLK2 297/4885CLK1 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.